by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Preclinical respiratory efficacy studies are an important part of developing new treatments for diseases affecting the lungs and airways. Before a candidate progresses towards clinical development, researchers need evidence that it produces a relevant biological or...
by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Airway hyperresponsiveness is a key feature of asthma and an important endpoint in preclinical respiratory drug development. It describes an exaggerated narrowing of the airways in response to stimuli that produce a smaller response in healthy airways. Measuring this...
by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Developing a new respiratory therapeutic requires a clear understanding of disease biology, drug activity and the evidence needed to progress a candidate through preclinical development. For pharmaceutical and biotechnology companies, accessing the right preclinical...
by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Choosing the right respiratory CRO (Contract Research Organisation) can be an important decision for pharmaceutical and biotechnology companies developing new treatments for respiratory disease. Preclinical respiratory research involves more than selecting an...
by Virtus | Sep 5, 2026 | Respiratory Preclinical Research
Respiratory toxicology studies are an important component of preclinical drug development, particularly when a therapeutic is intended to treat diseases of the lungs and airways or is administered directly to the respiratory tract. Before a new respiratory therapeutic...
by Virtus | Sep 5, 2026 | Respiratory Preclinical Research
IND-enabling respiratory studies are an important part of the preclinical drug development process for new respiratory therapeutics. Before a potential treatment can progress into human clinical trials, pharmaceutical and biotechnology companies need appropriate...